Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Total Debt (2016 - 2026)

Avanos Medical's Total Debt history spans 12 years, with the latest figure at $10.2 million for Q4 2025.

  • On a quarterly basis, Total Debt rose 8.51% to $10.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 8.51% increase, with the full-year FY2025 number at $10.2 million, up 8.51% from a year prior.
  • Total Debt hit $10.2 million in Q4 2025 for Avanos Medical, up from $9.4 million in the prior quarter.
  • Over the last five years, Total Debt for AVNS hit a ceiling of $232.5 million in Q4 2022 and a floor of $4.7 million in Q2 2022.
  • Historically, Total Debt has averaged $29.8 million across 5 years, with a median of $9.4 million in 2024.
  • Biggest five-year swings in Total Debt: soared 78.85% in 2022 and later tumbled 96.3% in 2023.
  • Tracing AVNS's Total Debt over 5 years: stood at $130.0 million in 2021, then soared by 78.85% to $232.5 million in 2022, then tumbled by 96.3% to $8.6 million in 2023, then rose by 9.3% to $9.4 million in 2024, then rose by 8.51% to $10.2 million in 2025.
  • Business Quant data shows Total Debt for AVNS at $10.2 million in Q4 2025, $9.4 million in Q3 2025, and $9.4 million in Q2 2025.